Serotonin increased Nrf-2 activity in control hPASMCs; yet, in PAH-hPASMCs, a statistically significant increase in Nrf-2 activity was not observed with serotonin treatment (Figure 2C). Here, NFE2L2 is linked to pulmonary arterial hypertension.